curriculum vitae

Arzu Ulu, Ph.D., M.Sc.
Publications and Abstracts
First author publications
1. Ulu A, Lee KSS, Miyabe C, Yang J, Hammock BG, Dong H, Hammock BD (2013). An omega-3
epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II dependent hypertension
(submitted to J Cardiovasc Pharmacol).
2. Ulu A, Dong H, Miyabe C, Liu JY, Inoue H, Weiss RH, Imig JD, Hammock BD. Antagonistic
effects of high salt intake on the efficacy of sEH inhibitors in angiotensin-II dependent
hypertension (in preparation).
3. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Liu JY, Weiss RH,
Chiamvimonvat N, Imig JD, Hammock BD (2013). Anti-inflammatory effects of omega-3
polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II dependent
hypertension. J Cardiovasc Pharmacol.; 62(3):285-97.
4. Ulu A, Appt SE, Morisseau C, Hwang SH, Rose TE, Jones PD, Dong H, Miyabe C, Lango J, Yang
J, Tsai HJ, Fortenbach C, Adams MR, Hammock BD. Pharmacokinetics, and in vivo potency of
urea soluble epoxide hydrolase inhibitors in Cynomolgus monkeys (2012). Br J Pharmacol.;165
(5):1401-12.
5. Koeners MP*, Wesseling S*, Ulu A*, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA.
Soluble epoxide hydrolase (Ephx2) in the generation and maintenance of high blood
pressure in spontaneously hypertensive rats (2011). Am J Physiol Endocrinol
Metab.;300(4):E691-8. *Shared first authorship.
6. Ulu A*, Davis BB*, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Hammock BD, Weiss RH.
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in Apo-e
knockout mouse model (2008). J Cardiovas Pharmacol;52(4):314-23. *Shared first authorship.
7. Ulu A, Gunal D, Tiras S, Egin Y, Deda G, Akar N. EPCR gene A3 haplotype and elevated soluble
endothelial protein C receptor (EPCR) levels in Turkish pediatric stroke patients (2007).
Thrombosis Research;120(1):47-52.
Other co-authored publications
8. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X,
Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD (2013). Epoxy
metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
Proc Natl Acad Sci U S A.;110(16):6530-5.
9. Patent application in progress: Hammock BD, Zhang G, Inceoglu B, Ulu A (2013). Inhibition of
soluble epoxide hydrolase (sEH) enhances the beneficial effects of omega-3 lipids.
10. Guedes AG, Morisseau C, Sole A, Soares JH, Ulu A, Dong H, Hammock BD (2013). Use of a
soluble epoxide hydrolase inhibitor as adjunctive analgesic in a horse with laminitis. Vet
Anaesth Analg.;40(4):440-8.
11. Morisseau C, Schebb NH, Dong H, Ulu A, Aronov PA, Hammock BD. Role of soluble epoxide
hydrolase phosphatase activity in the metabolism of lysophosphatidic acids (2012). Biochem
Biophys Res Commun.;419(4):796-800.
12. Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chiamvimonvat N, Hammock BD.
Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial
triclocarban in a murine model (2011). Toxicol Appl Pharmacol.;255(2):200-6.
13. Inceoglu B, Wagner K, Schebb NH, Morisseau C, Jinks SL, Ulu A, Hegedus C, Rose T,
Brosnan R, Hammock BD. Analgesia mediated by soluble epoxide hydrolase inhibitors is
dependent on cAMP (2011). Proc Natl Acad Sci U S A.;108(12):5093-7.
14. Wang YX, Ulu A, Zhang LN, Hammock BD. Soluble epoxide hydrolase in atherosclerosis
(2010). Curr Atheroscler Rep.;12(3):174-83.
15. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, Hammock BD. Inhibition of
1
soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5lipoxygenase activation protein inhibitor in a murine model (2010). Biochem Pharmacol;
15;79(6):880-7.
16. Inceoglu B, Jinks SL, Ulu A, Hegedus CM, Georgi K, Schmelzer KR, Wagner K, Jones PD,
Morisseau C, Hammock BD. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two
distinct analgesic pathways (2008). Proc Natl Acad Sci U S A.;105(48):18901-6.
17. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of Factor V 1691 G-A (Leiden) and
prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients
(2007). Journal of Thrombosis and Thrombolysis;23(1):31-4.
18. Eroglu A, Ulu A, Akar N. Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer
patients with and without
thrombosis
(2006). Journal of Thrombosis
and
Thrombolysis;22(2):111-2.
19. Eroglu A, Ulu A, Kurtman C, Cam R, Akar N. 23 bp endothelial protein C receptor (EPCR) gene
insertion mutation in cancer patients with and without thrombosis (2006). American Journal of
Hematology;81(3): 220.
20. Eroglu A, Kurtman C, Ulu A, Cam R, Akar N. Factor V Leiden and PT G20210A mutations in cancer
patients with and without thrombosis (2005). Journal of Thrombosis and Hemostasis;3:1- 2.
21. Eroglu A, Ulu A, Erekul S, Akgul H, Akar N. PT G20210A and factor V Leiden mutations and
isolated limb perfusion-associated thrombosis in patients with soft tissue sarcoma (2004).
Thrombosis and Hemostasis;91:837-838.
National level publications
22. Ulu A, Egin Y, Akar N. The correlation between soluble endothelial protein C receptor (EPCR)
and tumor necrosis factor-alpha (TNF-) levels in vivo (2008). Turk Journal of
Hematology;25(2):108-109.
23. Akar N, Ulu A. Endothelial cell protein C receptor (EPCR) gene exon III, 23 bp insertion
mutation in Turkish Cypriots (2006). Turkish Journal of Hematology;23: 169-170.
24. Ulu A, Elsobky E, Elsayed M, Yildiz Z, Tekin M, Akar N. Frequency of five thrombophilic
polymorphisms in the Egyptian population (2006). Turkish Journal of Hematology; 23:100-103.
25. Ulu A, Yilmaz E, Akar E, Akar N. Factor V A4070G (His1299Arg) mutation in Turkish pediatric
patients with thrombosis (2005). Turkish Journal of Hematology; 22(4): 173-178.
26. M.Sc. thesis: “Factor V Leiden, FV 4070 A-G and Prothrombin 20210 G-A mutations among
pediatric thrombosis patients” (2004). Ankara University, Ankara, Turkey.
27. Ulu A, Yilmaz E, Akar E, Akar N. Homozygosity for the HR2 Haplotype: Is it a Risk Factor for
Thrombosis? (2003) Turkish Journal of Hematology;20(4):213-215.
Selected abstracts
1. Harris T, Ulu A, Davis BB, Weiss RH, Jung O, Fleming I, Busse R, Xu D, Chiamvimonvat N,
Hammock B.D. Soluble epoxide hydrolase and cardiovascular health (2008). American Heart
Association Young Investigator Forum (poster).
2. Terry C, Ulu A, Morisseau C, Hammock BD, Cheung AK, Weiss RH. Renal and vascular effects
of soluble epoxide hydrolase inhibitors: potential application to hemodialysis vascular access
stenosis (2007). The 9th Annual Winter Eicosanoid Conference, Baltimore, Maryland- USA
(poster).
3. Ulu A, Akar R, Emiroglu O, Ucanok K, Deda G, Akar E, Akar N. The determination of
endothelial protein C receptor gene 23 bp insertion in Turkish atherosclerotic patients (2004).
XXXI. Oral presentation at the National Hematology Congress, Istanbul-Turkey.
4. Ulu A, Akar R, Emiroglu O, Ucanok K, Akar E, Akar N. EPCR 23 bp insertion in atherosclerosis and
early MI (2004). Featured poster at the 18th International Congress on Thrombosis, Lubljana,
Slovenia.
5. Eroglu A, Kurtman C, Yildiz Z, Ulu A, Cam R, Akar N. Factor V Leiden and PT G20210A
mutations in cancer patients with thrombosis (2004). 12th Congress of the European Society of
Surgical Oncology, Budapest-Hungary (poster).
2
6. Ulu A, Akar R, Emiroglu O, Ucanok K, Deda G, Akar E, Akar N. The Distribution of EPCR gene 23 bp
insertion polymorphism among Anatolian and Turkish Cypriots both in healthy population and
atherosclerosis and pediatric thrombosis (2003). Oral presentation at the 4th International Congress
on Thrombosis, Hemostasis and Angiogenesis, Edirne-Turkey.
7. Ulu A, Akar E, Yılmaz E, Akar N. HR2 Haplotype 4070 A-G (FV 1299 His-Arg) in Turkish
Thrombosis Patients (Supplement to the Journal of Thrombosis and Hemostasis) (2003). 19th
Congress of the ISTH, Birmingham-UK (poster).
3